COVID-19 vaccine hesitancy - reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic
The ongoing coronavirus disease (COVID-19) vaccination drive aims to achieve global vaccination coverage that will help to control the pandemic. Therefore, the individuals who are reluctant to be vaccinated or forego COVID-19 vaccination can delay the progress of overall vaccination coverage, leading to slower vaccination rates and may create obstacles in global efforts to control the circulation of SARS-CoV-2 as unvaccinated individuals can act as reservoirs of SARS-CoV-2 and could drive further outbreaks. Vaccine hesitancy is one of the major threats that directly impact global health as it challenges our ability to eradicate infectious diseases and achieve significant herd immunity through vaccination. One of the strategies to counter vaccine hesitancy is to follow a multisectoral approach that involves the collaboration between various stakeholders, such as government, private companies, religious groups, and other agencies, to leverage the knowledge, expertise, and resources, thereby enabling the creation of longstanding public trust of vaccines.
| Errataetall: |
CommentIn: Hum Vaccin Immunother. 2022 Nov 30;18(5):2068337. - PMID 35481799 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 17(2021), 10 vom: 03. Okt., Seite 3495-3499 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dhama, Kuldeep [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 15.09.2021 Date Revised 07.01.2023 published: Print-Electronic CommentIn: Hum Vaccin Immunother. 2022 Nov 30;18(5):2068337. - PMID 35481799 Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2021.1926183 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327385065 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327385065 | ||
| 003 | DE-627 | ||
| 005 | 20231226203229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2021.1926183 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327385065 | ||
| 035 | |a (NLM)34191680 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dhama, Kuldeep |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 vaccine hesitancy - reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2021 | ||
| 500 | |a Date Revised 07.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Hum Vaccin Immunother. 2022 Nov 30;18(5):2068337. - PMID 35481799 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The ongoing coronavirus disease (COVID-19) vaccination drive aims to achieve global vaccination coverage that will help to control the pandemic. Therefore, the individuals who are reluctant to be vaccinated or forego COVID-19 vaccination can delay the progress of overall vaccination coverage, leading to slower vaccination rates and may create obstacles in global efforts to control the circulation of SARS-CoV-2 as unvaccinated individuals can act as reservoirs of SARS-CoV-2 and could drive further outbreaks. Vaccine hesitancy is one of the major threats that directly impact global health as it challenges our ability to eradicate infectious diseases and achieve significant herd immunity through vaccination. One of the strategies to counter vaccine hesitancy is to follow a multisectoral approach that involves the collaboration between various stakeholders, such as government, private companies, religious groups, and other agencies, to leverage the knowledge, expertise, and resources, thereby enabling the creation of longstanding public trust of vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a vaccine hesitancy | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Sharun, Khan |e verfasserin |4 aut | |
| 700 | 1 | |a Tiwari, Ruchi |e verfasserin |4 aut | |
| 700 | 1 | |a Dhawan, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Emran, Talha Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Rabaan, Ali A |e verfasserin |4 aut | |
| 700 | 1 | |a Alhumaid, Saad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 17(2021), 10 vom: 03. Okt., Seite 3495-3499 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2021 |g number:10 |g day:03 |g month:10 |g pages:3495-3499 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2021.1926183 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2021 |e 10 |b 03 |c 10 |h 3495-3499 | ||